Samsung Bioepis Co., Ltd. has received a recommendation from the European regulatory body for a second biosimilar Avastin (bevacizumab) product, although the strategic rationale or reason was not immediately clear.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending granting a pan-European...






